Download PDF
Zentralbl Gynakol 2001; 123(4): 179-185
DOI: 10.1055/s-2001-14774
Historisches, Pathogenese und Epidemiologie

J.A.Barth Verlag in Medizinverlage Heidelberg GmbH & Co.KG

HPV-Infektion und Zervixkarzinom - Epidemiologie, Nachweis und Immunologie

HPV and cervical cancer: Epidemiology, detection and immunological aspectsA. Schneider, M. Dürst, A. M. Kaufmann
  • Abteilung Frauenheilkunde der Friedrich-Schiller-Universität Jena (Direktor: Prof. Dr. A. Schneider)
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

Zusammenfassung

Bestimmte molekulargenetisch definierte Typen von humanen Papillomviren (HPV) verursachen in Interaktion mit anderen Kofaktoren das Zervixkarzinom. Alle bisher identifizierten Risikofaktoren für Neoplasien der cervix uteri verlieren im Vergleich mit HPV an Bedeutung. Neben HPV ist eine bisher noch nicht klassifizierte genetische Prädisposition wichtig. Der Nachweis von HPV im Abstrich erfolgt durch Identifizierung der Virus-DNA, wobei auf PCR basierende Verfahren die höchste Spezifität besitzen. Im Moment laufen erste Impfstudien mit therapeutischen Impfstoffen und Studien zur prophylaktischen Vakzinierung sind in Planung.

HPV and cervical cancer: Epidemiology, detection and immunological aspects

Summary

Certain molecularly defined types of human papillomaviruses (HPV) induce, by interaction with additional cofactors, cervical cancer. In comparison to infection with HPV, all risk factors identified to date are less important. In addition to HPV a not yet classified genetic predisposition is important. Identification of HPV in cervical smears is done by detection of viral DNA. PCR based methods have the highest specificity. Currently, first vaccination studies with therapeutic vaccines are performed and phase I/II trials for prophylactic vaccination show promising results.

Schlüsselwörter

Zervixkarzinom - Epidemiologie - HPV-Nachweis - Immuntherapie

Key words

Cervical cancer - epidemiology - HPV detection - immuno therapy

Literatur

  • 1 Altmann A, Jochmus-Kudielka I, Frank R, Gausepohl H, Moebius U, Gissmann L, Meuer S C. Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7.  Eur J Cancer. 1992;  28 326-333
    PubMedGoogle Scholar
  • 2 ALTS Group . Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group [see comments].  J Natl Cancer Inst. 2000;  92 397-402
    CrossrefPubMedGoogle Scholar
  • 3 Anonymous. Cancer of the cervix: death by incompetence [editorial].  Lancet. 1985;  II 363-364
    PubMedGoogle Scholar
  • 4 Statistisches Landesamt Saarland .Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1992. 1995; Sonderheft 180
    Google Scholar
  • 5 Barrasso R, De Brux J, Croissant O, Orth G. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia.  N Engl J Med. 1987;  317 916-923
    PubMedGoogle Scholar
  • 6 Bauer H M, Ting Y, Greer C E, Chambers J C. et al . Genital human papillomavirus infection in female university students as determined by a PCR-based method [see comments].  JAMA. 1991;  265 472-477
    CrossrefPubMedGoogle Scholar
  • 7 Bauer H M, Hildesheim A, Schiffman M H. et al . Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon.  Sex Transm Dis. 1993;  20 274-278
    PubMedGoogle Scholar
  • 8 Benton C, Shahidullah H, Hunter J AA. Human papillomavirus in the immunosuppressed.  Papillomavirus Report. 1992;  3 23-26
    PubMedGoogle Scholar
  • 9 Borysiewicz L K, Fiander A, Nimako M. et al . A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments].  Lancet. 1996;  347 1523-1527
    CrossrefPubMedGoogle Scholar
  • 10 Bosch F X, Manos M M, Munoz N. et al . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.  J Natl Cancer Inst. 1995;  87 796-802
    CrossrefPubMedGoogle Scholar
  • 11 Bryans R E, Boyles D A, Fidler H K. The influence of a cytological screening program upon the incidence of invasive aquamous cell carcinoma of the cervix in British Columbia.  Am J Obstet Gynecol. 1964;  88 898
    PubMedGoogle Scholar
  • 12 Campo M S, Grindlay G J, O'Neil B W, Chandrachud L M, McGarvie G M, Jarrett W F. Prophylactic and therapeutic vaccination against a mucosal papillomavirus.  J Gen Virol. 1993;  74 945-953
    PubMedGoogle Scholar
  • 13 Chandrachud L M, O'Neil B W, Jarrett W F, Grindlay G J, McGarvie G M, Campo M S. Humoral immune response to the E7 protein of bovine papillomavirus type 4 and identification of B-cell epitopes.  Virology. 1994;  200 98-104
    CrossrefPubMedGoogle Scholar
  • 14 Christensen N D, Kreider J W, Kan N C, DiAngelo S L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes.  Virology. 1991;  181 572-579
    CrossrefPubMedGoogle Scholar
  • 15 Coleman N, Birley H D, Renton A M, Hanna N F, Ryait B K, Byrne M, Taylor-Robinson D, Stanley M A. Immunological events in regressing genital warts.  Am J Clin Pathol. 1994;  102 768-774
    PubMedGoogle Scholar
  • 16 de Gruijl T D, Bontkes H J, Stukart M J. et al . T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.  J Gen Virol. 1996;  77 2183-2191
    PubMedGoogle Scholar
  • 17 Fredericks B D, Balkin A, Daniel H W, Schonrock J, Ward B, Frazer I CH. Transmission of human papillomaviruses from mother to child [see comments].  Aust NZ J Obstet Gynaecol. 1993;  33 30-32
    CrossrefPubMedGoogle Scholar
  • 18 Hall S, Lorincz A, Shah F, Sherman M E, Abbas F, Paull G, Kurman R J, Shah K V. Human papillomavirus DNA detection in cervical specimens by hybrid capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix.  Gynecol Oncol. 1996;  62 353-359
    CrossrefPubMedGoogle Scholar
  • 19 Halpert R, Fruchter R G, Sedlis A, Butt K, Boyce J G, Sillman F H. Human papillomavirus and lower genital neoplasia in renal transplant patients.  Obstet Gynecol. 1986;  68 251-258
    PubMedGoogle Scholar
  • 20 Handley J, Dinsmore W, Maw R, Corbell R, Burrows D, Bharucha H, Swann A, Bingham A. Anogenital warts in prepubertal children; sexual abuse or not? [see comments].  Int J STDAIDS. 1993;  4 271-279
    PubMedGoogle Scholar
  • 21 Hildesheim A, Schiffman M H, Gravitt P E. et al . Persistence of type-specific human papillomavirus infection among cytologically normal women [see comments].  J Infect Dis. 1994;  169 235-240
    PubMedGoogle Scholar
  • 22 Jacobs M V, Snijders P J, van der Brule A J, Helmerhorst T J, Meijer C J. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay meth rapid detection of 14 high risk human papillomavirus genoty cervical scrapings.  J Clin Microbiol. 1997;  35 791-795
    PubMedGoogle Scholar
  • 23 Jarrett W F, Smith K T, O'Neil B W. et al . Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins.  Virology. 1991;  184 33-42
    PubMedGoogle Scholar
  • 24 Jochmus I, Osen W, Altmann A. et al . Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.  J Gen Virol. 1997;  78 1689-1695
    PubMedGoogle Scholar
  • 25 Kadish A S, Romney S L, Ledwidge R. et al . Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific.  J Gen Virol. 1994;  75 2277-2284
    PubMedGoogle Scholar
  • 26 Knowles G, O'Neil B W, Campo M S. Phenotypical characterization of lymphocytes infiltrating regressing papillomas.  J Virol. 1996;  70 8451-8458
    PubMedGoogle Scholar
  • 27 Koutsky L A, Galloway D A, Holmes K K. Epidemiology of genital human papillomavirus infection.  Epidemiol Rev. 1988;  10 122-163
    PubMedGoogle Scholar
  • 28 Koutsky L A, Holmes K K, Critchlow C W. et al . A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.  N Engl J Med. 1992;  327 1272-1278
    PubMedGoogle Scholar
  • 29 Ley C, Bauer H M, Reingold A, Schiffman H M, Chambers J C, Tashiro C J, Manos M M. Determinants of genital human papillomavirus infection in young women [see comments].  J Natl Cancer Inst. 1991;  83 997-1003
    PubMedGoogle Scholar
  • 30 Lin Y L, Borenstein L A, Selvakumar R, Ahmed R, Wettstein F O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.  Virology. 1992;  187 612-619
    CrossrefPubMedGoogle Scholar
  • 31 Magnusson P K, Sparen P, Gyllensten U B. Genetic link to cervical tumours [letter].  Nature. 1999;  400 29-30
    CrossrefPubMedGoogle Scholar
  • 32 McGarvie G M, Grindlay G J, Chandrachud L M, O'Neil B W, Jarrett W F, Campo M S. T-cell responses to BPV-4 E7 during infection and mapping of T-cell epitopes.  Virology. 1995;  206 504-510
    CrossrefPubMedGoogle Scholar
  • 33 Moscicki A B, Palefsky J, Gonzales J, Schoolnik G K. Human papillomavirus infection in sexually active adolescent females: prevalence and risk factors.  Pediatr Res. 1990;  28 507-513
    CrossrefPubMedGoogle Scholar
  • 34 Möhner M. Krebsinzidenz in der DDR 1988/1989. In: Anonymous (ed) Atlas der Krebsinzidenz in der DDR 1961-1989: Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt, Thüringen und des Freistaates Sachsen beim Bundesgesundheitsamt. Ullstein Mosby, Berlin 1994; 1-4047
    Google Scholar
  • 35 Munoz N, Bosch F X, de Sanjose S. et al . The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain.  Int J Cancer. 1992;  52 743-749
    PubMedGoogle Scholar
  • 36 Nindl I, Benitez-Bribiesca L, Berumen J. et al . Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.  Arch Virol. 1994;  137 341-353
    CrossrefPubMedGoogle Scholar
  • 37 Nonnenmacher B, Hubbert N L, Kirnbauer R. et al . Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.  J Infect Dis. 1995;  172 19-24
    PubMedGoogle Scholar
  • 38 Oriel J D. Natural history of genital warts. 1971 [classical article] [see comments].  Sex Transm Infect. 2000;  76 (Suppl 1) S 21
    PubMedGoogle Scholar
  • 39 Palefsky J M, Gonzales J, Greenblatt R M, Ahn D K, Hollander H. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease.  JAMA. 1990;  263 2911-2916
    CrossrefPubMedGoogle Scholar
  • 40 Peters R K, Chao A, Mack T M, Thomas D, Bernstein L, Henderson B E. Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County.  J Natl Cancer Inst. 1986;  76 423-428
    PubMedGoogle Scholar
  • 41 Ponten J, Adami H O, Bergström R. et al . Strategies for global control of cervical cancer [see comments].  Int J Cancer. 1995;  60 1-26
    CrossrefPubMedGoogle Scholar
  • 42 Resnick R M, Cornelissen M T, Eichinger G H. et al . Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers.  J Natl Cancer Inst. 1990;  82 1477-1484
    PubMedGoogle Scholar
  • 43 Ressing M E, Sette A, Brandt R M. et al . Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.  J Immunol. 1995;  154 5934-5943
    PubMedGoogle Scholar
  • 44 Ressing M E, van Driel W J, Celis E. et al . Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.  Cancer Res. 1996;  56 582-588
    PubMedGoogle Scholar
  • 45 Richart R M. Cervical intraepithelial neoplasia.  Pathol Annu. 1973;  8 301-328
    PubMedGoogle Scholar
  • 46 Roman A, Fife K. Human papillomavirus DNA associated with foreskins of normal newborns.  J Infect Dis. 1986;  153 855-861
    PubMedGoogle Scholar
  • 47 Schiffman M H. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia.  J Natl Cancer Inst. 1992;  84 394-398
    CrossrefPubMedGoogle Scholar
  • 48 Schiffman M H, Bauer H M, Hoover R N. et al . Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia [see comments].  J Natl Cancer Inst. 1993;  85 958-964
    PubMedGoogle Scholar
  • 49 Schiffman M H, Herrero R, Hildesheim A. et al . HPV DNA testing cervical cancer screening: results from in a high province of Costa Rica.  JAMA. 2000;  283 87-93
    PubMedGoogle Scholar
  • 50 Schneider A, Kirchmayr R, de Villiers E M, Gissmann L. Subclinical human papillomavirus infections in male sexual partners of female carriers.  J Urol. 1988;  140 1431-1434
    PubMedGoogle Scholar
  • 51 Schneider A, Schlunck G. Detection and typing of genital papillomaviruses: nucleic acid hybridization and type-specific antigen detection. In: Gross G, Jablonska S, Pfister H, Stegner HE, (Eds). Genital papillomavirus infections: Advances in modern diagnosis and therapy. Springer, Heidelberg, New York, Tokyo 1989; 69-86
    Google Scholar
  • 52 Schneider A. Pathogenesis of genital HPV infection.  Genitourin Med. 1993;  69 165-173
    PubMedGoogle Scholar
  • 53 Schneider A, Wagner D. Infektionen der Frau mit genitalem humanem Papillomvirus.  Dtsch Ärztebl. 1993;  90 730-732
    PubMedGoogle Scholar
  • 54 Schneider A, Dürst M, Jochmus I, Gissmann L. Epidemiologie, Äthiologie und Prävention des Zervixkarzinoms.  Onkologe. 1998;  4 110-123
    CrossrefPubMedGoogle Scholar
  • 55 Schwartz S M, Weiss N S. Increased incidence of adenocarcinoma of the cervix in young women in the United States.  Am J Epidemiol. 1986;  124 1045-1047
    PubMedGoogle Scholar
  • 56 Sedlacek T V, Lindheim S, Eder C, Hasty L, Woodland M, Ludomirski A, Rando R F. Mechanism for human papillomavirus transmission at birth.  Am J Obstet Gynecol. 1989;  161 55-59
    CrossrefPubMedGoogle Scholar
  • 57 Selvakumar R, Borenstein L A, Lin Y L, Ahmed R, Wettstein F O. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas.  J Virol. 1995;  69 602-605
    PubMedGoogle Scholar
  • 58 Selvakumar R, Schmitt A, Iftner T, Ahmed R, Wettstein F O. Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression.  J Virol. 1997;  71 5540-5548
    PubMedGoogle Scholar
  • 59 Snijders P J, van den Brule A J, Schrijnemakers H F, Snow G, Meijer C J, Walboomers J M. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes.  J Gen Virol. 1990;  71 173-181
    PubMedGoogle Scholar
  • 60 Sparen P, Gustafsson L, Friberg L G, Ponten J, Bergstrom R, Adami H O. Improved control of invasive cervical cancer in Sweden over six decades by earlier clinical detection and better treatment.  J Clin Oncol. 1995;  13 715-725
    PubMedGoogle Scholar
  • 61 St Louis M E, Icenogle J P, Manzila T, Kamenga M, Ryder R W, Hayward W L, Reeves W C. Genital types of papillomavirus in children of women with HIV-1 infection in Kinshasa, Zaire.  Int J Cancer. 1993;  54 181-184
    PubMedGoogle Scholar
  • 62 Steele J C, Stankovic T, Gallimore P H. Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.  J Virol. 1993;  67 2799-2806
    PubMedGoogle Scholar
  • 63 van Wijngaarden W J, Duncan I D, Hussain K A. Screening for cervical neoplasia in Dundee and Angus: 10 years on.  Br J Obstet Gynaecol. 1995;  102 137-142
    PubMedGoogle Scholar
  • 64 Vermund S H, Kelley K F, Klein R S, Reingold A R, Schreiber K, Munk G, Burk R D. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection.  Am J Obstet Gynecol. 1991;  165 392-400
    PubMedGoogle Scholar
  • 65 Walboomers J M, Jacobs M V, Manos M M. et al . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;  189 12-19
    Google Scholar
  • 66 Wright T CJ, Lörincz A, Ferris D G, Richart R M, Ferenczy A, Mielzynka I, Borgotta L. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears.  Am J Obstet Gynecol. 1998;  178 962-966
    PubMedGoogle Scholar
  • 67 zur Hausen H, Richart R M. IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses Lyon, Frankreich.  1995;  64 277-28?
    PubMedGoogle Scholar

Prof. Dr. A. Schneider,MPH 

Abteilung für Frauenheilkunde
Klinik für Frauenheilkunde und Geburtshilfe
Friedrich-Schiller-Universität Jena

Bachstr. 18

D-07740 Jena





      >